188 related articles for article (PubMed ID: 37760460)
1. IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma.
Klingbeil KD; Tang JP; Graham DS; Lofftus SY; Jaiswal AK; Lin TL; Frias C; Chen LY; Nakasaki M; Dry SM; Crompton JG; Eilber FC; Rao DS; Kalbasi A; Kadera BE
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760460
[TBL] [Abstract][Full Text] [Related]
2. Liposarcoma: Clinico-pathological analysis, prognostic factors and survival in a series of 307 patients treated at a single institution.
Muratori F; Frenos F; Bettini L; Matera D; Mondanelli N; Scorianz M; Cuomo P; Scoccianti G; Beltrami G; Greto D; Livi L; Baldi G; Roselli G; Capanna R; Campanacci DA
J Orthop Sci; 2018 Nov; 23(6):1038-1044. PubMed ID: 30007495
[TBL] [Abstract][Full Text] [Related]
3. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Stacchiotti S; Van der Graaf WTA; Sanfilippo RG; Marreaud SI; Van Houdt WJ; Judson IR; Gronchi A; Gelderblom H; Litiere S; Kasper B
Cancer; 2022 Aug; 128(15):2932-2938. PubMed ID: 35561319
[TBL] [Abstract][Full Text] [Related]
4. Dedifferentiation within well-differentiated liposarcoma of the extremity or trunk: Implications for clinical management.
Tseng WW; Barretta F; Baia M; Barisella M; Radaelli S; Callegaro D; Yoon DH; Fiore M; Gronchi A
J Surg Oncol; 2021 Oct; 124(5):838-845. PubMed ID: 34254688
[TBL] [Abstract][Full Text] [Related]
5. Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.
Lahat G; Anaya DA; Wang X; Tuvin D; Lev D; Pollock RE
Ann Surg Oncol; 2008 Jun; 15(6):1585-93. PubMed ID: 18398663
[TBL] [Abstract][Full Text] [Related]
6. Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma.
Yen CC; Chen SC; Hung GY; Wu PK; Chua WY; Lin YC; Yen CH; Chen YC; Wang JY; Yang MH; Chao Y; Chang MC; Chen WM
Int J Oncol; 2019 Oct; 55(4):938-948. PubMed ID: 31485600
[TBL] [Abstract][Full Text] [Related]
7. Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma.
Jung E; Fiore M; Gronchi A; Grignol V; Pollock RE; Chong SS; Chopra S; Hamilton AS; Tseng WW
Anticancer Res; 2018 Jun; 38(6):3535-3542. PubMed ID: 29848707
[TBL] [Abstract][Full Text] [Related]
8. Influence of age and subtype in outcome of operable liposarcoma.
Greto D; Saieva C; Loi M; Terziani F; Visani L; Garlatti P; Lo Russo M; Muntoni C; Becherini C; Topulli J; Campanacci D; Beltrami G; Scoccianti G; Muratori F; Bonomo P; Desideri I; Francolini G; Livi L
Radiol Med; 2019 Apr; 124(4):290-300. PubMed ID: 30421387
[TBL] [Abstract][Full Text] [Related]
9. Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma.
Jagosky MH; Anderson CJ; Symanowski JT; Steuerwald NM; Farhangfar CJ; Baldrige EA; Benbow JH; Livingston MB; Patt JC; Ahrens WA; Kneisl JS; Kim ES
Cancer Med; 2023 Mar; 12(6):7029-7038. PubMed ID: 36464833
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin.
Beird HC; Wu CC; Ingram DR; Wang WL; Alimohamed A; Gumbs C; Little L; Song X; Feig BW; Roland CL; Zhang J; Benjamin RS; Hwu P; Lazar AJ; Futreal PA; Somaiah N
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610390
[TBL] [Abstract][Full Text] [Related]
11. Identification of IGF2BP3 as an Adverse Prognostic Biomarker of Gliomas.
Sun C; Zheng X; Sun Y; Yu J; Sheng M; Yan S; Zhu Q; Lan Q
Front Genet; 2021; 12():743738. PubMed ID: 34721530
[TBL] [Abstract][Full Text] [Related]
12. Retroperitoneal Dedifferentiated Liposarcoma.
Dehner CA; Hagemann IS; Chrisinger JSA
Am J Clin Pathol; 2021 Oct; 156(5):920-925. PubMed ID: 34125170
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of
Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Replication-Dependent Histone Signifies a Subset of Dedifferentiated Liposarcoma with Increased Aggressiveness.
Yoo Y; Park SY; Jo EB; Choi M; Lee KW; Hong D; Lee S; Lee CR; Lee Y; Um JY; Park JB; Seo SW; Choi YL; Kim S; Lee SG; Choi M
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206586
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution.
Mussi C; Collini P; Miceli R; Barisella M; Mariani L; Fiore M; Casali PG; Gronchi A
Cancer; 2008 Oct; 113(7):1657-65. PubMed ID: 18704991
[TBL] [Abstract][Full Text] [Related]
16. IGF2BP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer.
Huang W; Zhu L; Huang H; Li Y; Wang G; Zhang C
BMC Cancer; 2023 Feb; 23(1):116. PubMed ID: 36732736
[TBL] [Abstract][Full Text] [Related]
17. Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma.
Tseng WW; Chopra S; Engleman EG; Pollock RE
Front Oncol; 2016; 6():134. PubMed ID: 27376027
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
Nessim C; Raut CP; Callegaro D; Barretta F; Miceli R; Fairweather M; Blay JY; Strauss D; Rutkowski P; Ahuja N; Gonzalez R; Grignani G; Quagliuolo V; Stoeckle E; Lahat G; De Paoli A; Pillarisetty VG; Canter RJ; Mullen JT; Pennacchioli E; van Houdt W; Swallow CJ; Schrage Y; Cardona K; Fiore M; Gronchi A; Bagaria SP
Ann Surg Oncol; 2021 Nov; 28(12):7854-7863. PubMed ID: 33907921
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of perioperative inflammatory index as a prognostic factor for patients with retroperitoneal soft tissue sarcoma.
Matsui Y; Matsuda A; Maejima A; Shinoda Y; Nakamura E; Komiyama M; Fujimoto H
Int J Clin Oncol; 2022 Jun; 27(6):1093-1100. PubMed ID: 35319075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
